What Is Pacemaker Syndrome? Symptoms, Causes, & Treatment

Pacemaker syndrome is a collection of symptoms that develop when a pacemaker disrupts the normal coordination between the upper and lower chambers of the heart. Rather than a device malfunction, it is a mismatch between the way the pacemaker stimulates the heart and the way the heart naturally needs to contract. Symptoms range from mild fatigue and dizziness to fainting and heart failure, and the condition is more common than many patients or even clinicians expect.

How Pacemaker Syndrome Develops

In a healthy heart, the upper chambers (atria) contract a fraction of a second before the lower chambers (ventricles), pushing blood downward in a coordinated sequence. That timing matters. When a pacemaker stimulates only the ventricles, as older single-chamber (VVI) devices do, the ventricles may fire while the atria are still relaxed or, worse, the electrical signal can travel backward from the ventricles up into the atria. This backward conduction forces the atria to contract against closed heart valves, sending blood in the wrong direction.

The downstream effects cascade quickly. The atria cannot properly fill the ventricles, so cardiac output drops. Pressure builds in the atria and backs up into the veins of the neck and lungs. Stretch receptors in the heart walls and major blood vessels detect the abnormal pressures and trigger reflexes that dilate blood vessels, lowering blood pressure at exactly the wrong moment. Hormonal responses compound the problem, and the net result is a patient who feels lightheaded, short of breath, or faint despite having a functioning pacemaker.¹

An early hemodynamic study confirmed that ventricular pacing reduces cardiac output because the normal atrial “kick” is lost, and that the low blood pressure seen in pacemaker syndrome patients is tied to an atrial reflex that suppresses normal blood vessel tone.² In other words, the heart is not just pumping less blood; the body’s vascular system is also relaxing when it should be tightening up, creating a double hit.

Recognizing the Symptoms

Pacemaker syndrome does not always look the same from patient to patient. Some people notice symptoms immediately after their device is implanted; others develop them gradually over weeks or months, especially if the percentage of paced heartbeats increases over time. The hallmark signs include shortness of breath, dizziness, fatigue, visible pulsations in the neck or abdomen, and a type of abnormal venous pulse called cannon waves, where the jugular vein in the neck visibly bulges with each heartbeat.³

At the mild end, patients describe feeling “off” during exertion or noticing they tire more easily than before the pacemaker was placed. At the severe end, people experience near-fainting or full syncope, fluid buildup in the lungs, and signs of overt heart failure.¹ The irony is hard to miss: the device was implanted to prevent symptoms from a slow heart rate, and now it is creating a new set of problems.

A particularly tricky feature is that symptoms can be intermittent. If the pacemaker only activates some of the time, a patient may feel fine during periods when their own natural rhythm is in charge and symptomatic only when the device kicks in. One case report described a patient with tachy-brady syndrome whose pacemaker syndrome appeared only during episodes of ventricular pacing, not during every heartbeat.⁴ This intermittent pattern can delay diagnosis because the symptoms come and go unpredictably.

Who Is at Higher Risk

Not every patient with a ventricular pacemaker develops pacemaker syndrome, which raises the question of who is more vulnerable. The Mode Selection Trial (MOST), one of the largest studies to examine this, tracked patients with sinus node dysfunction who received ventricular-based pacing. Among those patients, several factors predicted whether pacemaker syndrome would appear. A slower underlying sinus rate and a higher programmed pacemaker rate both raised the risk, as did a higher percentage of paced beats after implantation.⁵

What did not predict pacemaker syndrome was equally interesting. Prior heart failure, baseline ejection fraction, and the degree of blood pressure drop during VVI pacing at the time of implantation were all non-predictors in that study.⁵ So a doctor cannot simply look at a patient’s heart function before implantation and confidently predict who will be affected. The syndrome’s occurrence depends more on how the device interacts with the patient’s underlying rhythm than on how sick the heart was to begin with.

The Problem With Right Ventricular Pacing Beyond Pacemaker Syndrome

Pacemaker syndrome is not the only concern with ventricular-only pacing. When the pacing lead sits at the tip of the right ventricle, as it traditionally does, the electrical activation pattern it produces is abnormal. Instead of the heart’s normal rapid, coordinated contraction, the left and right ventricles contract out of sync. Over time, this dyssynchrony can weaken the heart muscle. One study found that the degree of dyssynchrony measured shortly after high-dose right ventricular pacing began could predict a later decline in the heart’s pumping function in patients who started with a normal ejection fraction.⁶

The severity of this dyssynchrony also depends on the patient’s pre-existing electrical conduction pattern. Patients who had a normal conduction pattern or a left bundle branch block before pacing experienced significantly more dyssynchrony from right ventricular pacing than patients who already had a right bundle branch block.⁷ The practical upshot is that the harm of right ventricular pacing is not uniform across all patients. Some hearts tolerate it reasonably well; others are set on a path toward weakening even when the pacemaker is technically working perfectly.

This realization has reshaped how cardiologists think about pacemaker selection. Even dual-chamber pacemakers that preserve the atrial-ventricular timing sequence still deliver their ventricular stimulus to the right ventricular apex, which means they can produce the same dyssynchrony problem. One review noted that the expected benefits of dual-chamber pacing over single-chamber pacing are partly offset by the dyssynchrony caused by a high percentage of ventricular pacing in the dual-chamber mode itself.⁸

How Pacemaker Syndrome Is Diagnosed

There is no single blood test or imaging scan that definitively diagnoses pacemaker syndrome. Instead, diagnosis relies on a combination of the patient’s symptoms, the timing of those symptoms in relation to pacemaker activity, and the response to reprogramming the device. Doctors look at the electrocardiogram for evidence of ventricular pacing with retrograde conduction into the atria, check for blood pressure drops during paced beats, and assess whether symptoms improve when the pacing mode is changed.

Echocardiography can help. One study used transesophageal echocardiography to evaluate patients with clinical pacemaker syndrome before and after reprogramming from a ventricular mode to a dual-chamber mode. All patients experienced improvement in symptoms after the switch to dual-chamber pacing, and follow-up imaging confirmed the hemodynamic benefit.⁹ The improvement after reprogramming is itself a strong diagnostic clue. If a patient feels markedly better once the pacemaker is switched to a mode that restores atrial-ventricular coordination, the diagnosis is essentially confirmed.

Part of what makes diagnosis tricky is that patients may not connect their symptoms to the pacemaker. Fatigue and mild dizziness are common complaints in the elderly population that typically receives pacemakers, and both patients and doctors sometimes attribute these symptoms to aging or other medical conditions rather than to the pacing mode. The syndrome can also overlap with other causes of heart failure, making it easy to miss unless someone specifically thinks to check pacemaker programming.

Subclinical Pacemaker Syndrome

Perhaps the most surprising finding in the pacemaker syndrome literature is that many patients who report no complaints still benefit from a pacing upgrade. A randomized study took patients who were apparently satisfied with long-term single-chamber ventricular pacing and upgraded them to dual-chamber devices. The results suggested that up to three-quarters of those “asymptomatic” patients had measurable improvements after the switch, pointing to a form of subclinical pacemaker syndrome that patients had simply adapted to or learned to live with.¹⁰

That study also found that the DDI pacing mode, a dual-chamber variant that does not track atrial activity, offered little benefit over ventricular-only pacing. In practice, this means the advantage comes specifically from modes that sense the atrium and time the ventricular beat accordingly, not simply from having two leads in the heart.¹⁰

The existence of subclinical pacemaker syndrome complicates clinical decision-making. If most patients with ventricular pacing are functioning below their potential without realizing it, the case for defaulting to dual-chamber devices becomes stronger. But dual-chamber devices are more expensive, more complex to implant, and add a second lead that can develop its own complications. One case report described pacemaker syndrome that developed after an atrial lead fractured in a dual-chamber device, effectively converting it to a single-chamber ventricular pacemaker.³ So even patients with dual-chamber systems are not entirely immune if something goes wrong with the atrial lead.

Treatment Options

The first-line treatment for pacemaker syndrome is reprogramming the device. If the patient has a dual-chamber pacemaker, switching to a mode that preserves atrial-ventricular timing often resolves symptoms quickly. Programming strategies that encourage the heart’s own conduction system to work whenever possible, minimizing the percentage of ventricular-paced beats, can also help.⁸ Many modern dual-chamber pacemakers have algorithms specifically designed to reduce unnecessary ventricular pacing.

If the patient has a single-chamber ventricular pacemaker, the device may need to be upgraded to a dual-chamber system. In the PASE trial, roughly a quarter of elderly patients assigned to ventricular pacing crossed over to dual-chamber pacing because of pacemaker syndrome symptoms.¹¹ That crossover rate is notable because the trial specifically enrolled patients who were considered candidates for either mode, meaning these were not extreme cases. A quarter of a general pacemaker population developing symptoms severe enough to require a mode change underlines how common this problem is.

An interesting finding from the same trial: patients with sinus node dysfunction (where the problem is a sluggish natural pacemaker in the atrium) showed clearer quality-of-life benefits from dual-chamber pacing than patients whose indication was atrioventricular block (where the problem is a faulty connection between the atria and ventricles).¹¹ This distinction matters because it suggests the clinical benefit of dual-chamber pacing is not the same for everyone and depends on why the pacemaker was needed in the first place.

Conduction System Pacing as a Newer Alternative

Because even dual-chamber pacemakers can cause dyssynchrony when they pace the right ventricular apex, researchers have been exploring ways to pace the heart’s own electrical highways more directly. Conduction system pacing places the ventricular lead at a spot that engages the heart’s natural wiring, either at the His bundle (the main trunk of the conduction system) or along the left bundle branch (one of the two main branches that carry signals into the ventricles). Both approaches produce a more natural contraction pattern than conventional right ventricular pacing.¹²

A prospective randomized trial comparing conduction system pacing to right ventricular pacing in patients with severe conduction disease found that conduction system pacing led to a smaller decline in the heart’s pumping function after one year.¹³ And a large study using Medicare data showed even more striking results: patients who received conduction system pacing had roughly 30% fewer heart failure hospitalizations and about a third lower all-cause mortality at six months compared to those who received traditional right ventricular pacing.¹⁴

Conduction system pacing is not yet the default at every hospital. The technique requires specialized training, the leads are placed differently than conventional leads, and long-term data are still accumulating. But the trajectory is clear: by preserving the heart’s natural contraction sequence, conduction system pacing sidesteps the dyssynchrony problem that underlies both pacemaker syndrome and the subtler long-term harm of right ventricular pacing.

Cost and the Case for Dual-Chamber Devices

Health systems have long grappled with whether the added cost of dual-chamber pacemakers is justified. A systematic review and economic evaluation estimated that over five years, a dual-chamber system costs roughly £700 more than a single-chamber device when all complication and clinical-event costs are included. The cost per quality-adjusted life year (QALY) was estimated at around £8,500 to £9,500 over five years and dropped to about £5,500 over ten years, both well within the range generally considered acceptable by policymakers. Under more conservative assumptions, the figure rose to around £30,000 per QALY.¹⁵

A U.S.-based analysis from the MOST trial projected that over a lifetime, dual-chamber pacing would increase quality-adjusted life expectancy by about 0.14 years at an incremental cost of roughly $6,800 per QALY gained, and bootstrap analyses found dual-chamber pacing was cost-effective in over 90% of simulations at standard willingness-to-pay thresholds.¹⁶ Both analyses noted that pacemaker syndrome is a critical driver of these calculations. If you assume pacemaker syndrome occurs less often or is less severe, the economic advantage of dual-chamber devices shrinks. This is one reason the difficulty in standardizing the diagnosis has practical consequences beyond the clinic.¹⁵

Living With a Pacemaker and Ongoing Monitoring

Even after pacemaker syndrome is treated or avoided through appropriate device selection, living with a pacemaker involves regular follow-up. Traditionally, that has meant in-office visits every few months to check device function, battery status, and lead integrity. A randomized trial from Japan tested whether replacing most of those in-person visits with continuous remote monitoring over two years was safe and found that it did not increase major cardiovascular events while reducing the use of healthcare resources.¹⁷ Remote monitoring can also catch problems like lead fractures or mode-switching issues earlier, potentially flagging a return of pacemaker syndrome before the patient even recognizes it.

The psychological dimension deserves attention too. A study of pacemaker patients found that about 40% screened positive for depression, and those with depression were more likely to report poor health status and fatigue.¹⁸ While that study was conducted during the COVID-19 pandemic, which likely inflated the numbers, the broader point holds: symptoms like fatigue and malaise overlap between pacemaker syndrome and depression, and sorting out what is device-related versus mood-related can be genuinely difficult. If reprogramming the pacemaker does not resolve persistent fatigue, screening for depression is a reasonable next step.

When Ventricular-Only Pacing Still Makes Sense

Despite everything above, there are patients for whom single-chamber ventricular pacing remains the right choice. Patients with permanent atrial fibrillation already lack organized atrial contractions, so a dual-chamber device offers no advantage. Similarly, patients who only need pacing very occasionally for brief symptomatic pauses may do fine with a simpler device, since the pacemaker fires so rarely that pacemaker syndrome never has time to develop. The randomized study on subclinical pacemaker syndrome recommended that ventricular-only pacing be reserved specifically for patients with very intermittent symptomatic bradycardia or atrial fibrillation with a good heart rate response during exercise.¹⁰

For everyone else, the trend in pacemaker therapy has been moving steadily toward preserving natural heart physiology as much as possible, whether through dual-chamber devices programmed to minimize ventricular pacing, conduction system pacing that engages the heart’s own wiring, or a combination of both. Pacemaker syndrome served as an early warning that pacing the heart is not just about preventing it from going too slowly. How you pace matters as much as whether you pace at all.